Milestone Pharmaceuticals Inc. $MIST Shares Sold by Propel Bio Management LLC

Propel Bio Management LLC trimmed its position in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 19.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,118,321 shares of the company’s stock after selling 1,006,569 shares during the period. Milestone Pharmaceuticals makes up about 7.1% of Propel Bio Management LLC’s holdings, making the stock its 5th biggest holding. Propel Bio Management LLC owned 4.84% of Milestone Pharmaceuticals worth $8,319,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Strategic Family Wealth Counselors L.L.C. purchased a new stake in Milestone Pharmaceuticals during the 4th quarter worth $25,000. Eaton Financial Holdings Company LLC purchased a new stake in Milestone Pharmaceuticals during the 4th quarter worth $26,000. Bank of America Corp DE boosted its position in Milestone Pharmaceuticals by 200,550.0% during the 3rd quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after purchasing an additional 16,044 shares during the period. Creative Planning boosted its position in Milestone Pharmaceuticals by 74.6% during the 2nd quarter. Creative Planning now owns 23,410 shares of the company’s stock worth $45,000 after purchasing an additional 10,000 shares during the period. Finally, Bay Rivers Group boosted its position in Milestone Pharmaceuticals by 72.9% during the 4th quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock worth $58,000 after purchasing an additional 12,170 shares during the period. 86.18% of the stock is currently owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Stock Down 4.7%

MIST stock opened at $1.23 on Friday. Milestone Pharmaceuticals Inc. has a 52 week low of $1.00 and a 52 week high of $3.06. The company has a market capitalization of $153.14 million, a price-to-earnings ratio of -1.81 and a beta of 0.95. The firm’s 50-day moving average is $1.64 and its two-hundred day moving average is $1.88. The company has a current ratio of 9.18, a quick ratio of 9.09 and a debt-to-equity ratio of 1.61.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its earnings results on Wednesday, May 13th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.26). The business had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $30.12 million. On average, analysts forecast that Milestone Pharmaceuticals Inc. will post -0.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Zacks Research lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Friday, May 15th. Wall Street Zen lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Sunday, May 17th. Wells Fargo & Company cut their target price on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating on the stock in a research note on Thursday, May 14th. Finally, Raymond James Financial started coverage on shares of Milestone Pharmaceuticals in a research note on Friday, April 10th. They issued a “strong-buy” rating and a $6.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $7.25.

Insider Activity

In other Milestone Pharmaceuticals news, CEO Joseph Oliveto sold 36,500 shares of the firm’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $2.26, for a total value of $82,490.00. Following the completion of the transaction, the chief executive officer directly owned 446,244 shares in the company, valued at $1,008,511.44. This trade represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.50% of the stock is owned by corporate insiders.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.